The p85 regulatory subunit of PI3K mediates cAMP-PKA and insulin biological effects on MCF-7 cell growth and motility

Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Di Zazzo, E ^a   Feola, A ^b,c   Zuchegna, C ^b   Romano, A ^b   Donini, C F ^d   Bartollino, S ^a   Costagliola, C ^a   Frunzio, R ^b   Laccetti, P ^b   Di Domenico, M ^c,e   Porcellini, A ^b  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; PROTEIN P85 PHOSPHATIDYLINOSITOL 3 KINASE; SERINE; UNCLASSIFIED DRUG; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOLOGICAL ACTIVITY; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; GLUCONEOGENESIS; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOLECULAR MECHANICS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CELL MOTION; DRUG EFFECTS; INTRACELLULAR SPACE; METABOLISM; PHOSPHORYLATION; PROTEIN TRANSPORT;

CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INTRACELLULAR SPACE; MCF-7 CELLS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 84904613154     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/565839     Document Type: Article

References (45)

1. Hemkens L. G., Grouven U., Bender R., Günster C., Gutschmidt S., Selke G. W., Sawicki P. T., Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009 52 9 1732 1744 10.1007/s00125-009-1418-4 2-s2.0-68449104156
2. Currie C. J., Poole C. D., Gale E. A. M., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 52 9 1766 1777 10.1007/s00125-009-1440-6 2-s2.0-68449094325
3. Coughlin S. S., Calle E. E., Teras L. R., Petrelli J., Thun M. J., Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. The American Journal of Epidemiology 2004 159 12 1160 1167 10.1093/aje/kwh161 2-s2.0-2942520997 (Pubitemid 38747263)
4. Calle E. E., Rodriguez C., Walker-Thurmond K., Thun M. J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine 2003 348 17 1625 1638 10.1056/NEJMoa021423 2-s2.0-0037464510 (Pubitemid 36459468)
5. Reaven G. M., Pathophysiology of insulin resistance in human disease. Physiological Reviews 1995 75 3 473 486 2-s2.0-0029037649
6. Papa V., Pezzino V., Costantino A., Belfiore A., Giuffrida D., Frittitta L., Vannelli G. B., Brand R., Goldfine I. D., Vigneri R., Elevated insulin receptor content in human breast cancer. Journal of Clinical Investigation 1990 86 5 1503 1510 10.1172/JCI114868 2-s2.0-0025066641 (Pubitemid 20372597)
7. Novosyadlyy R., Lann D. E., Vijayakumar A., Rowzee A., Lazzarino D. A., Fierz Y., Carboni J. M., Gottardis M. M., Pennisi P. A., Molinolo A. A., Kurshan N., Mejia W., Santopietro S., Yakar S., Wood T. L., LeRoith D., Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Research 2010 70 2 741 751 10.1158/0008-5472.CAN-09-2141 2-s2.0-76549136489
8. Fierz Y., Novosyadlyy R., Vijayakumar A., Yakar S., LeRoith D., Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 2010 59 3 686 693 10.2337/db09-1291 2-s2.0-77950354885
9. Zhang H., Fagan D. H., Zeng X., Freeman K. T., Sachdev D., Yee D., Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010 29 17 2517 2527 10.1038/onc.2010.17 2-s2.0-77951879658
10. Cantley L. C., The phosphoinositide 3-kinase pathway. Science 2002 296 5573 1655 1657 10.1126/science.296.5573.1655 2-s2.0-0037205048 (Pubitemid 34579158)
11. Cain R. J., Ridley A. J., Phosphoinositide 3-kinases in cell migration. Biology of the Cell 2009 101 1 13 29 10.1042/BC20080079 2-s2.0-58149395054
12. Krasilnikov M. A., Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry 2000 65 1 59 67 2-s2.0-0033628571
13. Hellyer N. J., Cheng K., Koland J. G., ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochemical Journal 1998 333 3 757 763 2-s2.0-0032142749 (Pubitemid 28398546)
14. McGlade C. J., Ellis C., Reedijk M., Anderson D., Mbamalu G., Reith A. D., Panayotou G., End P., Bernstein A., Kazlauskas A., Waterfield M. D., Pawson T., SH2 domains of the p85 α subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Molecular & Cellular Biology 1992 12 3 991 997 2-s2.0-0026576375 10.1128/MCB.12.3.991
15. Ciullo I., Diez-Roux G., Di Domenico M., Migliaccio A., Avvedimento E. V., cAMP signaling selectively influences Ras effectors pathways. Oncogene 2001 20 10 1186 1192 10.1038/sj.onc.1204219 2-s2.0-0035826187 (Pubitemid 32226244)
16. Cosentino C., Di Domenico M., Porcellini A., Cuozzo C., De Gregorio G., Santillo M. R., Agnese S., Di Stasio R., Feliciello A., Migliaccio A., Avvedimento E. V., p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival. Oncogene 2007 26 14 2095 2103 10.1038/sj.onc.1210027 2-s2.0-34047126322 (Pubitemid 46514751)
17. De Gregorio G., Coppa A., Cosentino C., Ucci S., Messina S., Nicolussi A., D'Inzeo S., Di Pardo A., Avvedimento E. V., Porcellini A., The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals. Oncogene 2007 26 14 2039 2047 10.1038/sj.onc.1210011 2-s2.0-34047121208 (Pubitemid 46514747)
18. French A. P., Mills S., Swarup R., Bennett M. J., Pridmore T. P., Colocalization of fluorescent markers in confocal microscope images of plant cells. Nature Protocols 2008 3 4 619 628 10.1038/nprot.2008.31 2-s2.0-42049116064 (Pubitemid 351516758)
19. Franke T. F., Hornik C. P., Segev L., Shostak G. A., Sugimoto C., PI3K/Akt and apoptosis: size matters. Oncogene 2003 22 56 8983 8998 10.1038/sj.onc.1207115 2-s2.0-1642471831 (Pubitemid 38121699)
20. Coffer P. J., Jin J., Woodgett J. R., Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochemical Journal 1998 335 1 1 13 2-s2.0-0032189381 (Pubitemid 28477043)
21. Manning B. D., Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. Journal of Cell Biology 2004 167 3 399 403 10.1083/jcb.200408161 2-s2.0-8444224619 (Pubitemid 39489047)
22. Kohn A. D., Summers S. A., Birnbaum M. J., Roth R. A., Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. The Journal of Biological Chemistry 1996 271 49 31372 31378 10.1074/jbc.271.49.31372 2-s2.0-0029908016 (Pubitemid 26408588)
23. Jackson J. G., White M. F., Yee D., Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. The Journal of Biological Chemistry 1998 273 16 9994 10003 10.1074/jbc.273.16.9994 2-s2.0-0032540288 (Pubitemid 28183101)
24. Luo J., Cantley L. C., The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Cell Cycle 2005 4 10 1309 1312 10.4161/cc.4.10.2062 2-s2.0-26444620098 (Pubitemid 41437108)
25. Luo J., Field S. J., Lee J. Y., Engelman J. A., Cantley L. C., The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. Journal of Cell Biology 2005 170 3 455 464 10.1083/jcb.200503088 2-s2.0-23744456586 (Pubitemid 41126944)
26. Taniguchi C. M., Winnay J., Kondo T., Bronson R. T., Guimaraes A. R., Alemán J. O., Luo J., Stephanopoulos G., Weissleder R., Cantley L. C., Kahn C. R., The phosphoinositide 3-kinase regulatory subunit p85 α can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Research 2010 70 13 5305 5315 10.1158/0008-5472.CAN-09-3399 2-s2.0-77954367305
27. Shepherd P. R., Withers D. J., Siddle K., Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochemical Journal 1998 333 part 3 471 490 2-s2.0-0032143284 (Pubitemid 28398511)
28. Ueki K., Algenstaedt P., Mauvais-Jarvis F., Kahn C. R., Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85 α regulatory subunit. Molecular and Cellular Biology 2000 20 21 8035 8046 10.1128/MCB.20.21.8035-8046.2000 2-s2.0-0033780412
29. Ikegami Y., Inukai K., Awata T., Asano T., Katayama S., SH3 domain of the phosphatidylinositol 3-kinase regulatory subunit is responsible for the formation of a sequestration complex with insulin receptor substrate-1. Biochemical and Biophysical Research Communications 2008 365 3 433 438 10.1016/j.bbrc.2007.10.187 2-s2.0-36549068627 (Pubitemid 350181674)
30. Neal C. L., Xu J., Li P., Mori S., Yang J., Neal N. N., Zhou X., Wyszomierski S. L., Yu D., Overexpression of 14-3-3 ζ in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 2012 31 7 897 906 10.1038/onc.2011.284 2-s2.0-84857113294
31. Donini C. F., Di Zazzo E., Zuchegna C., di Domenico M., D'Inzeo S., Nicolussi A., Avvedimento E. V., Coppa A., Porcellini A., The p85 α regulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and migration. International Journal of Oncology 2012 40 5 1627 1635 10.3892/ijo.2012.1383 2-s2.0-84860283503
32. Morali O. G., Delmas V., Moore R., Jeanney C., Thiery J. P., Larue L., IGF-II induces rapid β -catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001 20 36 4942 4950 10.1038/sj.onc.1204660 2-s2.0-0035899466 (Pubitemid 32769784)
33. Kabuta T., Hakuno F., Asano T., Takahashi S., Insulin receptor substrate-3 functions as transcriptional activator in the nucleus. Journal of Biological Chemistry 2002 277 9 6846 6851 10.1074/jbc.M107058200 2-s2.0-0036510379 (Pubitemid 34953067)
34. Soler A. P., Thompson K. A., Smith R. M., Jarett L., Immunological demonstration of the accumulation of insulin, but not insulin receptors, in nuclei of insulin-treated cells. Proceedings of the National Academy of Sciences of the United States of America 1989 86 17 6640 6644 10.1073/pnas.86.17.6640 2-s2.0-0001029405 (Pubitemid 19236326)
35. Ma Z., Gibson S. L., Byrne M. A., Zhang J., White M. F., Shaw L. M., Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Molecular and Cellular Biology 2006 26 24 9338 9351 10.1128/MCB.01032-06 2-s2.0-33845422458 (Pubitemid 44904428)
36. Leroith D., Insulin-like growth factor I receptor signaling-overlapping or redundant pathways? Endocrinology 2000 141 4 1287 1288 10.1210/en.141.4.1287 2-s2.0-0034457923 (Pubitemid 32269094)
37. Razzini G., Berrie C. P., Vignati S., Broggini M., Mascetta G., Brancaccio A., Falasca M., Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. The FASEB Journal 2000 14 9 1179 1187 2-s2.0-0034113153 (Pubitemid 30350400)
38. Fox E. M., Miller T. W., Balko J. M., Kuba M. G., Sánchez V., Smith R. A., Liu S., González-Angulo A. M., Mills G. B., Ye F., Shyr Y., Manning H. C., Buck E., Arteaga C. L., A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Research 2011 71 21 6773 6784 10.1158/0008-5472.CAN-11- 1295 2-s2.0-80155131176
39. Quayle S. N., Lee J. Y., Cheung L. W. T., Ding L., Wiedemeyer R., Dewan R. W., Huang-Hobbs E., Zhuang L., Wilson R. K., Ligon K. L., Mills G. B., Cantley L. C., Chin L., Somatic Mutations of PIK3R1 Promote Gliomagenesis. PLoS ONE 2012 7 11 e49466 10.1371/journal.pone.0049466 2-s2.0-84869118340
40. Li L., Plummer S. J., Thompson C. L., Tucker T. C., Casey G., Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clinical Cancer Research 2008 14 3 633 637 10.1158/1078-0432.CCR-07-1211 (Pubitemid 351231141)
41. Hildebrandt G., Zierski J., Csecsei G., Mueller H. W., Stracke H., Results of continuous long term intravenous application of octreotide via an implantable pump system in acromegaly resistent to operative and X-ray therapy. Acta Neurochirurgica 1992 117 3-4 160 165 10.1007/BF01400614 2-s2.0-0026662438
42. Kelly K. L., Ruderman N. B., Insulin-stimulated phosphatidylinositol 3-kinase. Association with a 185-kDa tyrosine-phosphorylated protein (IRS-1) and localization in a low density membrane vesicle. Journal of Biological Chemistry 1993 268 6 4391 4398 2-s2.0-0027412618 (Pubitemid 23072984)
43. Feola A., Cimini A., Migliucci F., Iorio R., Zuchegna C., Rothenberger R., Cito L., Porcellini A., Unteregger G., Tombolini V., Giordano A., Di Domenico M., The inhibition of p85 α PI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells. Journal of Cellular Biochemistry 2013 114 9 2114 2119 10.1002/jcb.24558 2-s2.0-84881382328
44. Torella D., Gasparri C., Ellison G. M., Curcio A., Leone A., Vicinanza C., Galuppo V., Mendicino I., Sacco W., Aquila I., Surace F. C., Luposella M., Stillo G., Agosti V., Cosentino C., Avvedimento E. V., Indolfi C., Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85 α PI3K. The American Journal of Physiology-Heart and Circulatory Physiology 2009 297 6 H2015 H2025 10.1152/ajpheart.00738.2009 2-s2.0-72249097487
45. Keely P. J., Westwick J. K., Whitehead I. P., Der C. J., Parise L. V., Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997 390 6660 632 636 10.1038/37656 2-s2.0-0031459917 (Pubitemid 28016201)